▲ Talipexole is a dopamine D2 receptor agonist, with activity at both pre- and postsynaptic D2 receptors. The drug also has α2-adrenoceptor agonist activity.
▲ In a primate model of Parkinson’s disease, talipexole dose-dependently improved motor activity and parkinsonian symptoms, and beneficial effects were additive when combined with levodopa.
▲ Clinical trials with talipexole in patients with Parkinson’s disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.
▲ In a large comparative trial in patients with Parkinson’s disease, talipexole was associated with a higher response rate and a lower incidence of gastrointestinal adverse events than bromocriptine, although drowsiness was more common among talipexole recipients.
▲ The most frequently reported adverse events associated with talipexole are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints such as nausea, gastrointestinal discomfort and loss of appetite.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Cedarbaum JM, Schleifer LS. Drugs for Parkinson’s disease, spasticity, and acute muscle spasms. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 463–84
Hashimoto T, Kuriyama K, Kohno Y. Effect of talipexole dihydrochloride (B-HT 920 CL2), bromocriptine mesylate and SND 919 on cerebral GABAergic and glutamatergic neurons [in Japanese]. The Clinical Report 1993; 27(13): 77–87
Kohno Y, Katamura Y, Nakazawa M, et al. The effects of talipexole on central monoamine receptors and metabolism in rats, with special reference to its effects on dopaminergic systems [in Japanese]. Pharmacometrics 1996; 52(5): 233–41
Drukarch B, Schepens E, Dolleman-Van der WMJ, et al. Lack of a dopamine autoreceptor selective profile of B-HT 920 in functional in vitro model systems of D2 receptors in rat striatum. Eur J Pharmacol 1990 Oct 9; 187: 257–69
Seutin V, Scuvee-Moreau J, Giesbers I, et al. Effect of BHT 920 on monoaminergic neurons of the rat brain: an electrophysiological in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 1990 Nov; 342: 502–7
Fink K, Gothert M. Modulation of N-methyl-D-aspartate (NMDA)-stimulated noradrenaline release in rat brain cortex by presynaptic α2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1993 Oct; 348: 372–8
Nishio H, Kohno Y, Fujii A, et al. 5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole. Gen Pharmacol 1996; 27(5): 779–85
Kulkarni SK, Chopra K. The dopaminergic actions of B-HT 920. Methods Find Exp Clin Pharmacol 1990 Mar; 12: 99–102
Anden NE, Grabowska-Anden M, Liljenberg B. On the presence of autoreceptors on dopamine neurons in different brain regions. J Neural Transm 1983; 57: 129–37
Anden NE, Nilsson H, Ros E, et al. Effects of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain. Acta Pharmacol Toxicol Copenh 1983 Jan; 52: 51–6
Anden NE, Grabowskaanden M. B-HT-920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors. J Neural Transm 1990; 79: 209–14
Clarke PB, Wyder KJ, Jakubovic A, et al. Effects of B-HT 920 on nigrostriatal and mesolimbic dopamine systems in normosensitive and supersensitive rats. Br J Pharmacol 1990 Mar; 99: 509–15
Imperato A, Tanda G, Frau R, et al. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J Pharmacol Exp Ther 1988 Apr; 245: 257–64
Robertson GS, Tham C-S, Wilson C, et al. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 1993 Mar; 264: 1344–51
Imperato A, Di-Chiara G. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur J Pharmacol 1988 Nov 8; 156: 385–93
Matsubayashi H, Amano T, Hongjing Y, et al. Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons. Psychopharmacology 1995 Aug; 120(4): 369–75
Todo N, Momiyama T, Amano T, et al. Excitation by talipexole, a dopamine D2 agonist, of caudate nucleus neurons activated by nigral stimulation. Life Sci 1994; 54(14): 957–66
Anden NE, Grabowska-Anden M. Stimulation of D1 dopamine receptors reveals direct effects of the preferential dopamine autoreceptor agonist B-HT 920 on postsynaptic dopamine receptors. Acta Physiol Scand 1988 Oct; 134: 285–90
Chopra K, Kulkarni SK. Potentiation of dopamine receptor-mediated responses by B-HT 920 in mice. Arch Int Pharmacodyn Ther 1988 Jul-Aug; 294: 46–55
Grabowska-Anden M, Anden NE. Inhibitory role of D-1 dopamine receptors for the jerks induced by B-HT 920 in rats. J Pharm Pharmacol 1987 Aug; 39: 660–1
Johansen PA, Clarkl D, White FJ. B-HT 920 stimulates postsynaptic D2 dopamine receptors in the normal rat: electrophysiological and behavioral evidence. Life Sci 1988; 43: 515–24
Pifl C, Hornykiewicz O. Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation. Eur J Pharmacol 1988 Jan 27; 146: 189–91
Verma A, Kulkarni SK. Concomitant D1-dopamine receptor activation (SKF-38393) unmasks D2-dopaminergic actions of B-HT-920 in mice. Indian J Exp Biol 1991 Feb; 29: 123–6
Irifune M, Nomoto M, Fukuda T. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets. Eur J Pharmacol 1993 Jul 20; 238: 235–40
Irifune M, Nomoto M, Fukuda T. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-DOPA and as chronic treatment. Eur J Pharmacol 1994 Oct 24; 264: 117–23
Kohno Y, Fukuzaki K, Kitahara K, et al. Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomologus monkeys with unilateral lesions in the ventromedial tegmentum. Eur J Pharmacol 1997; 319: 197–205
Pichler L, Kobinger W. Modulation of motor activity by α1- and α2-adrenoceptor stimulation in mice. Naunyn Schmiedebergs Arch Pharmacol 1981 Sep; 317: 180–2
Kobinger W, Pichler L. Investigation into different types of post and presynaptic α-adrenoceptors at cardiovascular sites in rats. Eur J Pharmacol 1980; 65: 393–402
Kinoshita T, Hatashita Y, Saito M. Clinical efficacy of talipexole di hydrochloride (B-HT 920 tablets) in Parkinson’s disease and a quantitative pharmaco-EEG study [in Japanese]. Shinyaku to Rinsho 1993 Jul; 42: 1338–50
Nishikawa T, Yamada S, Tsuda A, et al. Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans. Clin Neuropharmacol 1990 Jun; 13: 259–63
Kurakazu R, Shibata T, Oiwa Y, et al. Studies on the metabolic fate of [14C]talipexole (I). Absorption, distribution and excretion after single administration in rats [in Japanese]. Iyakuhin Kenkyu 1994; 25(3): 99–110
Kurakazu R, Shibata T, Oiwa Y, et al. Studies on the metabolic fate of [14C]talipexole (II). Absorption, distribution and excretion after multiple administration in rats [in Japanese]. Iyakuhin Kenkyu 1994; 25(2): 111–8
Kurakazu R, Sakai K, Kobayashi S, et al. Studies on the metabolic fate of [14C]talipexole (III). Metabolism in rats [in Japanese]. Iyakuhin Kenkyu 1994; 25(2): 119–33
Azuma J, Harada N, Sawamura A, et al. Phase I study of talipexole dihydrochloride (B-HT 920) [in Japanese]. Yakuri to Chiryo 1992; 20(12): 1–33
Nakanishi T, Kowa H, Mizuno Y. The clinical evaluation of B-HT 920 (talipexole hydrochloride) in Parkinson’s disease: a multi-centered double-blind comparative study vs. bromocriptine mesilate [in Japanese]. Rinsho Hyoka 1993; 21(1): 59–110
Mizuno Y, Kowa H, Nakanishi T. Preliminary study of B-HT 920, a novel dopamine agonist, for the treatment of Parkinson’s disease. Drug Invest 1993 Mar; 5: 186–92
Mizuno Y. Long-term clinical study of B-HT920 (talipexole hydrochloride) in patients with Parkinson’s disease, effect and safety in long-term administration [in Japanese]. Yakuri to Chiryo 1993 Jul; 21: 2295–315
Yanagisawa N, Kowa H, Mizuno Y, et al. Clinical phase II study of talipexole dihydrochloride (B-HT 920) tablet in Parkinson’s disease. Results of multicenter open study (step II) [in Japanese]. Rinsho Iyaku 1992; 8(12): 2841–67
Mizuno Y, Mori H, Kondo T. Practical guidelines for the drug treatment of Parkinson’s disease. CNS Drugs 1994 Jun; 1: 410–26
Rights and permissions
About this article
Cite this article
Plosker, G.L., Benfield, P. Talipexole. CNS Drugs 7, 410–416 (1997). https://doi.org/10.2165/00023210-199707050-00007
- Parkinsonian Symptom
- Caudate Nucleus Neuron